Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6870Lung Neoplasms 5102Small Cell Lung Carcinoma 1166Breast Neoplasms 855Neoplasms 762Colorectal Neoplasms 668Melanoma 566Ovarian Neoplasms 506Neoplasm Metastasis 480Pancreatic Neoplasms 472Adenocarcinoma of Lung 397Stomach Neoplasms 396Prostatic Neoplasms 370Head and Neck Neoplasms 367Carcinoma, Renal Cell 350Esophageal Neoplasms 337Squamous Cell Carcinoma of Head and Neck 325Mesothelioma, Malignant 324Colonic Neoplasms 293Mesothelioma 289Urinary Bladder Neoplasms 262Brain Neoplasms 254Uterine Cervical Neoplasms 243Triple Negative Breast Neoplasms 222Sarcoma 197Endometrial Neoplasms 196Carcinoma, Hepatocellular 186NSCLC 167Pleural Effusion, Malignant 160Kidney Neoplasms 160

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Non-small Cell Lung Cancer × Thoracic × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡